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Abstract
Background: Premature ventricular complexes (PVC) predict cardiovascular mortality among several adult
populations. Increased arrhythmia prevalence has been reported during controlled magnesium (Mg) depletion
studies in adults. We thus hypothesized that serum magnesium (sMg) concentrations are inversely associated with
the prevalence of PVC in adults at high cardiovascular risk.
Methods: Anthropometric, demographic and lifestyle characteristics were assessed in 750 Cree adults, aged > 18
yrs, who participated in an age-stratified, cross-sectional health survey in Quebec, Canada. Holter
electrocardiograms recorded heart rate variability and cardiac arrhythmias for two consecutive hours. Multivariate
logistic regression was used to evaluate the associations between sMg and PVC.
Results: PVC prevalence in adults with hypomagnesemia (sMg ≤ 0.70 mmol/L) was more than twice that of adults
without hypomagnesemia (50% vs. 21%, p = 0.015); results were similar when adults with cardiovascular disease
history were excluded. All hypomagnesemic adults with PVC had type 2 diabetes (T2DM). Prevalence of PVC
declined across the sMg concentration gradient in adults with T2DM only (p < 0.001 for linear trend). In
multivariate logistic regressions adjusted for age, sex, community, body mass index, smoking, physical activity,
alcohol consumption, kidney disease, antihypertensive and cholesterol lowering drug use, and blood
docosahexaenoic acid concentrations, the odds ratio of PVC among T2DM subjects with sMg > 0.70 mmol/L was
0.24 (95% CI: 0.06-0.98) p = 0.046 compared to those with sMg ≤ 0.70 mmol/L.
Conclusions: sMg concentrations were inversely associated with the prevalence of PVC in patients with T2DM in a
dose response manner, indicating that suboptimal sMg may be a contributor to arrhythmias among patients with
T2DM.
Keywords: Magnesium, Hypomagnesemia, Premature ventricular complexes, Premature ventricular beats, Ectopic
beats, Arrhythmia, Type 2 diabetes
Background
Premature ventricular complexes (PVC) are a relatively
common electrocardiographic abnormality presenting in
individuals with and without overt cardiovascular dis-
ease. In the latter case, PVC pathogenesis has tradition-
ally been considered idiopathic and in the absence of
severe clinical symptoms or structural cardiac abnormal-
ities, their presence benign [1,2]. Recent prospective stu-
dies evaluating the prognostic significance of PVC for
sudden and total cardiac death in apparently healthy
adults directly challenge this view. Among individuals
without history of heart disease or stroke, PVC counts
independently predicted future cardiac events or sudden
cardiac death compared to those without PVC [3-7].
These findings are consistent with hypothesis that PVC
may indicate electrical instability and increased
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common cause of sudden cardiac death.
Mg
2+ antagonizes calcium on the atrioventricular node
[8] and myocardial Mg
2+ deficiency decreases intracellu-
lar potassium, resulting in a less negative resting mem-
brane potential and enhanced vulnerability to
ventricular arrhythmia [9-11]. Two randomized, double-
blind crossover studies by USDA scientists showed that
reducing intake of dietary magnesium (Mg) in postme-
nopausal women in a metabolic unit to 33-50% of the
Mg recommended dietary allowance can induce heart
rhythm changes [12,13]. During the Mg depletion phase,
calcium, potassium, coppera n do t h e rn u t r i e n t sw e r e
concomitantly supplemented [12] and arrhythmias were
relieved by Mg supplementation, suggesting that Mg
insufficiency resulting from a diet that would not be
considered an atypical Western menu can induce
arrhythmias in older women.
In adults from the Framingham Offspring cohort free
of clinically apparent heart disease, total serum magne-
sium (sMg) was significantly inversely associated with
prevalence of complex or frequent PVC after adjustment
for multiple covariates, including serum potassium [14].
As type 2 diabetes (T2DM) is the most common condi-
tion associated with low sMg or hypomagnesemia (sMg
≤ 0.70 mmol/L) [15] and T2DM significantly increases
risk of PVC and sudden cardiac death [16], the associa-
tion between sMg and PVC may be modified by diabetic
status. However, testing for such potential effect modifi-
cation has not been reported previously.
We hypothesized that sMg concentrations are inver-
sely associated with the prevalence of PVC in a general
adult population at high cardiovascular risk, James Bay
Cree, and tested for effect modification by T2DM. Mg
intakes in Cree adults, particularly Cree men, are inade-
quate, with 93% of men 19-30 yrs and 100% of men ≥
31 yrs consuming less than the Mg recommended diet-
ary intake in some communities [17]. Due to rapid diet-
ary and lifestyle transition and consequent increasing
obesity rates, prevalence of T2DM among Cree is
among the highest in the world [18].
Methods
As u b s e to fa d u l t s( ≥ 18 yrs) of Cree descent from the
James Bay region of Quebec, Canada were selected from
a comprehensive aboriginal health survey ‘Nituu-
chischaayihitaau Aschii: A Multi-Community Environ-
ment and Health Longitudinal Study in Iiyiyiu Aschii.’
This cross-sectional study included fasting participants
from seven communities sampled between 2005-2009
for which sMg, covariates and 2-hr Holter electrocardio-
gram recordings were available. Bilingual Cree were
trained to conduct interviews and recruit participants.
Ethics for the health survey was obtained from the Cree
Board of Health and Social Services of James Bay
(CBHSSJB), Centre Hospitalier Universitaire de Québec
(Laval), and McGill universities. A research agreement
with communities was developed with the Cree Board
of Health and all individual study participants provided
informed written consent in Cree or English.
A total of 834 adults were assessed for anthropometric
measures, demographic and lifestyle variables (smoking,
alcohol consumption, exercise); sMg, full medical his-
tory, and Holter data (PVC) were available for 750
adults included in analysis. Individuals with missing
values did not differ significantly in covariate distribu-
tion from included individuals.
Variable assessment
Anthropometric variables were measured without shoes
by trained nurses. Height, measured in centimeters
using a graduated tape, and weight, determined using a
foot-to-foot bioelectrical impedance instrument (Tanita
Corp, Arlington Heights, IL, USA), were combined to
obtain body mass index (BMI). Exercise (frequency in
which individuals reported to engage in vigorous physi-
cal activity for at least 20 min at a time) was assessed by
a culturally adapted, short version of the International
Physical Activity Questionnaire validated in Cree adults
[19]. Smoking status (current, former or never) and
alcohol consumption (≥ 3 drinks/day, < 3 drinks day, or
never, of standard drinks of beer, liquor, wine, mixed
drinks, or shooters) were self-reported. As cellular and
animal models, epidemiological studies and clinical trials
suggest that long-chain polyunsaturated fatty acids exert
anti-arrhythmic effects [20,21], we tested the potentially
modifying effects of plasma eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) as nutritional covari-
ates in models. Medical charts for each participant were
reviewed and detailed cardiovascular event history or
conditions, metabolic conditions, cardiovascular drugs/
supplement use, and selected other conditions were
recorded. In characterizing the metabolic syndrome
(MetS), the consensus definition was used [22]. Adults
with T2DM had previously been diagnosed or presented
with fasting glucose (FG) concentrations ≥ 7 mmol/L.
Serum Mg was determined at Trace Elements Labora-
tory the London Laboratory Services group, London,
Ontario, Canada using the colorimetric endpoint
method with addition of xylidyl blue. Mg content was
measured photometrically as a function of the decrease
in xylidyl blue absorbance (laboratory reference range:
0.65-1.05 mmol/L). For the determination of EPA and
DHA concentrations, 200-μL aliquots of plasma were
extracted after the addition of chloroform: methanol
(2:1), in the presence of a known amount of internal
standard (diheptadecanoyl phospholipid). Total phos-
pholipids were isolated from the lipid extract via thin-
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heptane:isopropyl ether:acetic acid (60:40:3). Trans-
methylation with boron trifluoride and methanol pre-
ceded capillary gas-liquid chromatography to determine
fatty acid concentrations.
Frequency of premature ventricular beats, distinct
from supraventricular beats, were derived from a 2-hour
Holter monitoring system (GE Marquette Series 8500)
with a recording frequency of 128 Hz. Seven leads (deri-
vations V5, V1, and AVF) were installed when subjects
arrived to the clinic. During the 2-hour recording, sub-
jects remained at the clinic, completing anthropometric
measurements and lifestyle questionnaires.
Statistical approach
PVC prevalence for all adults ≥ 18 yrs (n = 750) on 2-
hour Holters was presented stratified by demographic,
anthropometric and lifestyle variables. We considered ≥
1 PVC/hr and > 6 PVC/hr recording as endpoints in
this high cardiometabolic risk sample; elevated risk for
sudden cardiac death was reported for high-risk partici-
pants in the Cardiovascular Health Study with > 153
PVC over 24 h, or about 6 events/hr [23].
Unadjusted prevalence of PVC across sMg groupings
for the entire sample and subgroups (with cardiovascu-
lar event history or conditions excluded, those with
T2DM, and MetS) was determined. Frequencies were
compared using X
2 tests or Fisher’s exact test when
sample sizes in contingency tables were small. Odds
ratios and 95% confidence intervals using multivariate
logistic regression for ≥ 1P V C / h ra n d>6P V C / h r
across the sMg concentration range for the whole popu-
lation were determined for five different covariate mod-
els. Hypomagnesemia was defined as sMg ≤ 0.70 mmol/
L. In subgroup analysis for adults with type 2 diabetes
and no prior cardiovascular disease (CVD) (n = 149),
only the odds ratio of ≥ 1 PVC/hr for normomagnese-
mic diabetics (sMg > 0.70 mmol/L) relative to the refer-
ence group of hypomagnesemic diabetics (sMg ≤ 0.70
mmol/L) were determined due to sample size con-
straints. For multivariate models, individuals with prior
CVD were defined as those with one or more condition
listed under “cardiovascular event history or conditions”
or taking CVD drugs in Table 1; hypertensives were
excluded from this definition. Additional sensitivity ana-
lysis was performed excluding adults with kidney dis-
ease, as this condition is associated with altered Mg
homeostasis and sMg concentrations [24].
Results
Our population included 441 women (58.8%) and 309
men (41.2%) with a mean age of 38.9 ± 14.8 yrs. Mean
BMI was 33.9 ± 7.0 kg/m
2.M o r et h a nh a l fo fa d u l t s
(51.3%) identified as current smokers. Hypertension was
the most common CVD condition (33.2%) and antihy-
pertensive drugs the most common class of CVD medi-
cations taken (24.4%). The percentage of adults with
MetS was 46.9%; prevalence of T2DM (diagnosed or FG
≥ 7 mmol/L) was 23.5% (Table 1).
Prevalence and frequency of PVC differed by smoking
status and was significantly higher in men, older partici-
pants, those with MetS or T2DM (p < 0.001 for each
covariate). PVC prevalence varied significantly with alco-
hol consumption, exercise and CVD history (excluding
hypertensives) (p < 0.05). There was a trend towards an
association between PVC and hypertension (p <0 . 1 0 )
Table 1 Medical chart review of adults (≥ 18 yrs) of the
general Cree population (n = 750)
Cardiovascular event history or conditions N
Ischemia/infarction 2
Cardiac insufficiency 4
Atrial fibrillation 3
Ventricular arrhythmia/tachycardia 5
Bradycardia 3
Ventricular hypertrophy 2
Angina 6
Hypertension (diagnosed) 185
(BP > 130/85 mmHg, or treatment of diagnosed) 249
Ischemic heart disease 6
Diseases of the pulmonary circulation 3
Stroke 4
Cerebrovascular diseases 11
Diseases of arteries, arterioles or capillaries 6
Cardiometabolic conditions
Metabolic syndrome 352
(excluding diagnosed type 2 diabetics/FG ≥ 7 mmol/L) 140
Gestational diabetes (history of) 23
Type 1 diabetes 1
Type 2 diabetes (diagnosed) 140
(diagnosed or FG ≥ 7 mmol/L) 176
Cardiovascular drug/supplement use
Antiplatelet 6
Antihypertensives 183
Diuretics (specifically) 62
Cholesterol-lowering drugs 79
Statins (specifically) 73
Multivitamins 41
Mg supplements 8
Hormonal or menstrual status
Post-menopausal 104
Hormone replacement therapy 1
Oral contraceptives 92
Currently breastfeeding 35
Other
Kidney disease 13
Cancer 6
Del Gobbo et al. Cardiovascular Diabetology 2012, 11:23
http://www.cardiab.com/content/11/1/23
Page 3 of 8but obesity was not significantly associated with PVC (p
= 0.39) (Table 2) nor was diuretics use (p = 0.63).
Unadjusted prevalence of PVC in adults with hypo-
magnesemia (sMg ≤ 0.70 mmol/L) was over twice that
of adults without hypomagnesemia (50% vs. 21%, p =
0.015); results were not different when adults with cardi-
ovascular disease history were excluded (Figure 1). In
multivariate logistic regression analyses for all adults (n
= 750), odds of ≥ 1 PVC/hr declined precipitously from
the hypomagnesemic reference group to 0.24 (95% CI:
0.07-0.87) in those with sMg 0.71-0.80 mmol/L in the
fully adjusted model (Model 5); risk did not substan-
tively change at higher sMg concentrations (Table 3).
Due to low sample size among the hypomagnesemic
reference group, it was not possible to further define the
sMg threshold associated with reduced odds ≥ 1 PVC in
this sample. Model covariates had little influence on
adjusted odds ratios; inclusion of EPA in any model had
no impact on estimates and was excluded.
Significantly decreased adjusted odds of > 6 PVC/hr
were observed in those with sMg above a sMg 0.75
mmol/L threshold in the whole population for all cov-
ariate models (Additional file 1). Odds of > 6 PVC/hr
for those with sMg 0.75-0.80 relative to those with <
0.75 mmol/L were 0.10 (95% CI: 0.02-0.46) in the fully
adjusted model (Model 5). A sMg threshold of 0.75
mmol/L was selected for this endpoint because ORs
were maximally reduced using this cutoff value (Addi-
tional file 2).
Further evaluation of the characteristics of hypomag-
nesemic subjects in this population revealed that all
individuals with PVC had T2DM. When participants
were stratified by diabetic status, prevalence of PVC
declined across the sMg concentration gradient in adults
with T2DM only (p < 0.001) (Figure 2). Decline in PVC
prevalence with increasing sMg among participants with
T2DM was significant even when hypomagnesemic
adults were excluded (p = 0.005). Addition of diabetic
medication use (metformin, gluconorm, or insulin) as
covariates had no influence on model estimates. While
only 1% of subjects without T2DM were hypomagnese-
m i c( n=5 ) ,n o n eo ft h e s es u b j e c t sh a dP V Cd u r i n g
recording. In the subgroup with MetS but without
T2DM, no significant difference in PVC prevalence
across the sMg concentration gradient was observed (p
= 0.84).
Among adults with T2DM and no CVD history (n =
149), individuals without hypomagnesemia (sMg > 0.70
mmol/L) had significantly lower risk of PVC on 2-hr
Holter recording in fully adjusted models [OR 0.24 (95%
CI: 0.06-0.98)] (Table 4). Sensitivity analysis excluding
remaining individuals with kidney disease (n = 4 without
CVD history) had no influence on model estimates.
Discussion
Hypomagnesemia & ventricular arrhythmias
Our finding of significantly elevated PVC prevalence in
adults with hypomagnesemia relative to adults without
reduced sMg is consistent with early clinical studies
reporting ventricular fibrillation and tachycardia in
hypomagnesemia [25,26]. Hypomagnesemia is an estab-
lished risk factor for polymorphic ventricular tachycar-
dia torsades de pointes [27] and intravenous magnesium
sulfate remains first-line therapy for tosades de pointes
associated with long QT interval according to current
ACC/AHA/ESC guidelines [28]. It has been suggested
that the trigger for torsades de pointes are PVC result-
ing from an early afterdepolarization generated during
the abnormally prolonged repolarization phase of
affected myocardium [29].
Table 2 Characteristics of Cree adults (≥ 18 yrs)
according to PVC prevalence during Holter
electrocardiogram (n = 750)
Characteristic No PVC
n = 591
1-6 PVC/hr
n = 118
> 6 PVC/hr
n=4 1
Sex
Male 217 (37%) 64 (54%) 28 (68%)
Female 374 (63%) 54 (46%) 13 (32%)***
Age (yrs)
18-30 194 (33%) 23 (19%) 5 (12%)
30-50 302 (51%) 44 (37%) 14 (34%)
≥ 50 95 (16%) 51 (43%) 22 (54%)***
BMI (kg/m
2)
<3 0 170 (29%) 36 (31%) 8 (20%)
≥ 30 421 (71%) 82 (69%) 33 (80%)
Smoking
Current 329 (56%) 40 (34%) 16 (39%)
Former 204 (34%) 61 (52%) 21 (51%)
Never 58 (10%) 17 (14%) 4 (10%)***
Alcohol
1
< 3 drinks/d 271 (46%) 48 (41%) 10 (24%)
Never 312 (54%) 69 (59%) 31 (76%)**
Exercise
≥ 4 times/wk 187 (32%) 37 (31%) 13 (32%)
1-3 times/wk 217 (36%) 32 (27%) 10 (24%)
None 187 (32%) 49 (42%) 18 (44%)**
Hypertension 153 (26%) 41 (35%) 15 (37%)*
CVD history
1 18 (3%) 7 (6%) 4 (10%)**
MetS
2 95 (16%) 30 (25%) 15 (37%)***
Diabetes
3 122 (21%) 37 (31%) 17 (41%)***
*p < 0.01 **p < 0.05 ***p < 0.001
1 Includes history of cardiovascular events/arrhythmia or CVD, excludes
hypertensives
2 Excludes diagnosed type 2 diabetics/FG ≥ 7 mmol/L
3 Includes diagnosed type 2 diabetes or FG ≥ 7 mmol/L
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mias in individuals with low sMg concentrations have
been criticized as lacking in evidence that the effect is
attributable to Mg alone as opposed to a combination of
hypomagnesemia and hypokalemia [30]. As we did not
measure serum potassium in our cross-sectional design,
this study provides no evidence to rebuke this claim,
particularly as hypomagnesemia and hypokalemia fre-
quently coexist and have similar etologies. In the Fra-
mingham Offspring cohort, apparently the only other
general population study associating sMg with PVC,
multivariate logistic regression analyses revealed that
both serum potassium and Mg concentrations, when
simultaneously entered into models, were inversely asso-
ciated with complex or frequent PVC occurrence (p <
0.04). Each standard deviation decrement in potassium
(0.48 mmol/L) or Mg (0.08 mmol/L) was associated
with a similar increase in odds PVC [27% (95% CI 6-
51%) for potassium, and 20% (95% CI 3-41%) for Mg]
[14]. From physiologic studies, Mg is an established reg-
ulator of major ion channels in the cardiovascular sys-
tem, including potassium, calcium, sodium, and others
[31]. Potassium is not effective in the suppression of
cardiac arrhythmia occurring in the presence of normal
Figure 1 PVC prevalence (%) during 2-hr Holters among adults
(n = 750) according to sMg concentrations (mmol/L)
1. Legend:
CVD excluded (grey bars) omits individuals with cardiovascular
event history or conditions. Difference in PVC prevalence among
participants with sMg ≤ 0.70 vs. > 0.70 mmol/L among all adults
(blue bars): p = 0.015; for CVD excluded (grey bars): p = 0.07.
Table 3 Adjusted odds ratios & 95% confidence intervals
for presence of ≥ 1 PVC on 2-hr Holters across the sMg
concentration range (n = 750)
sMg
(mmol/L)
≤ 0.7 0.71-0.80 0.81-0.90 > 0.90
Model 1 1.00 0.26 (0.07-0.88) 0.27 (0.08-0.93) 0.22 (0.06-0.81)
Model 2 1.00 0.25 (0.07-0.85) 0.26 (0.08-0.88) 0.19 (0.05-0.71)
Model 3 1.00 0.25 (0.07-0.85) 0.26 (0.08-0.88) 0.20 (0.05-0.73)
Model 4 1.00 0.24 (0.07-0.86) 0.25 (0.07-0.92) 0.19 (0.05-0.77)
Model 5 1.00 0.24 (0.07-0.87) 0.26 (0.07-0.93) 0.18 (0.04-0.73)
Model 1: adjusted for age and sex
Model 2: additionally adjusted for region and BMI
Model 3: additionally adjusted for smoking, physical activity, alcohol
consumption
Model 4: additionally adjusted for history of cardiovascular events/disease,
type 2 diabetes, kidney disease, antihypertensive and cholesterol lowering
drug use
Model 5: additionally adjusted for blood DHA
Figure 2 PVC prevalence (%) during 2-hr Holters among adults
without CVD (n = 652) by sMg concentrations (mmol/L) and
diabetic status
1. Legend: PVC prevalence declined with sMg
concentration in adults with T2DM (blue bars) only (p < 0.001 for
trend), even when hypomagnesemic adults were excluded (p =
0.005 for trend). While no nondiabetic (grey bars) had PVC during
monitoring, only 1% of nondiabetics were hypomagnesemic (sMg ≤
0.70 mmol/L)
Table 4 Effect of hypomagnesaemia in type 2 diabetics
without CVD history on adjusted odds ratios & 95%
confidence intervals for ≥ 1 PVC on 2-hr Holters (n =
149)
Type 2 diabetics
sMg ≤ 0.70 mmol/L
Type 2 diabetics
sMg > 0.70 mmol/L
Model 1 1.00 0.28 (0.08-0.98)
Model 2 1.00 0.25 (0.07-0.92)
Model 3 1.00 0.26 (0.07-1.04)
Model 4 1.00 0.25 (0.06-1.03)
Model 5 1.00 0.24 (0.06-0.98)
Model 1: adjusted for age and sex
Model 2: additionally adjusted for region and BMI
Model 3: additionally adjusted for smoking, physical activity, alcohol
consumption
Model 4: additionally adjusted for kidney disease, antihypertensive and
cholesterol lowering drug use
Model 5: additionally adjusted for blood DHA
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arrhythmias regardless of sMg concentration [30,32,33].
Irrespective of the degree to which prevalence of PVC
may differ due to sMg concentration independent of
other electrolytes, this study supports hypomagnesemia
as a risk factor for ventricular arrhythmias.
Magnesium & arrhythmias: T2DM as an effect modifier
Low serum Mg has been associated with T2DM [34],
but not metabolic states preceding T2DM [35,36], a
finding consistent with our data. In this sample, diabetic
status, but not MetS, was a major determinant of very
low sMg levels; 76% of all hypomagnesemic adults had
T2DM. While increased fractional excretion of Mg at
elevated insulin concentrations [37] may be at play in
both MetS and T2DM, mechanisms for Mg loss specific
to diabetes, such as renal Mg wasting secondary to
osmotic diuresis during glucosuria [38], might be asso-
ciated with comparatively greater reductions in sMg.
As T2DM is the most common condition associated
with low sMg [15] and diabetes significantly increases
risk of ventricular arrhythmias [16], there is theoretical
basis for the hypothesis that T2DM might modify the
association between sMg and PVC. Here, we provide
the first supporting evidence that T2DM is an impor-
tant effect modifier of the association between sMg
and PVC, with reductions in PVC prevalence across
the sMg gradient in T2DM only, driving the significant
associations observed in the entire population. While
t h eP V Co u t c o m ev a r i a b l e( >3 0P V C / h r ,m u l t i f o r mo r
repetitive) in the Framingham Offspring cohort was
different than endpoints assessed here and T2DM pre-
valence was high in our population, whether the signif-
icant association between sMg and PVC risk reported
in the Framingham cohort [14] might be modified by
i n c l u s i o no fT 2 D Ms t a t u sa sac o v a r i a t ei su n k n o w n .
Replication studies and explicit testing for potential
effect modification by diabetes in future analyses is
required.
In this work, risk of > 6 PVC/hr was maximally
reduced above a sMg threshold (0.75 mmol/L) within
the normal sMg concentrationr a n g ea n dp r e v a l e n c eo f
PVC declined across the normal sMg concentration gra-
dient in adults with T2DM. In other populations, signifi-
cantly reduced risk of ventricular arrhythmia [14],
sudden cardiac death [39] and cardiovascular disease
death [40,41] at elevated sMg concentrations have been
reported. Thus, the findings of this study are consistent
with evidence from other cross-sectional and prospec-
tive cohort studies reporting cardiovascular risk stratifi-
cation within the normal sMg range, with reduced risk
of both intermediary adverse outcomes and hard end-
points at higher sMg concentrations.
Limitations
Limitations of this study include use of sMg instead of
ionized Mg as a biomarker [26]; free intracellular Mg is
the fraction regulating enzyme pathways [27]. Although
sMg may not be a sensitive marker in reflecting mild
Mg inadequacy or the intracellular Mg pool, further
investigations evaluating the utility of sMg, an inexpen-
sive and simple measure, as a cardiovascular risk bio-
marker are appropriate.
Consistent cut-offs for the number or complexity
(multiforms, pairs, runs, R-on-T) of PVC per unit time
of Holter recording associated with mortality risk across
population groups of different ages, ethnicities or under-
lying cardiovascular risk have yet to be established [3-6].
Thus, a main limitation of this work is the uncertain
prognostic significance of PVC endpoints selected in
this high-risk population, which can be determined
through long term follow-up for incidence of ventricular
fibrillation, tachycardia, sudden cardiac death, or CVD
mortality. Other limitations include the use of short-
term (2 hr) Holter monitoring on a single occasion for
PVC detection, and unknown left ventricular ejection
fraction, the latter of which could have modulated pre-
valence of asymptomatic heart disease and PVC among
patients with diabetes. Generalizability of our findings
may be limited by the ethnic homogeneity of the sample
and high prevalence of T2DM relative to most other
general populations. Inclusion of other potentially rele-
vant unmeasured covariates, such as serum potassium
and other electrolytes, caffeine use, non-cardiovascular
drugs, or stress/anxiety might reduce residual confound-
ing. Consistency in sample demographics and CVD risk,
monitoring environments, duration and specific PVC
endpoints assessed in different populations will be
important in reducing heterogeneity among future stu-
dies and facilitating comparisons.
Conclusions
This study provides evidence that T2DM is an impor-
tant effect modifier of the association between sMg and
ventricular ectopy, with significant reductions in PVC
prevalence across the sMg gradient in adults with
T2DM. Diabetic status, but not MetS, was a major
determinant of very low sMg levels in this population.
PVC risk was particularly elevated in diabetic adults
with hypomagnesemia, suggesting that future interven-
tions to increase sMg concentrations among adults with
T2DM may confer protection against ventricular
arrhythmias. As hypomagnesemia is an under-diagnosed
electrolyte abnormality common in T2DM [42], appro-
priately powered randomized controlled clinical trials
are required to evaluate the potential of Mg to reduce
arrhythmias and cardiovascular risk.
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Additional file 1: Adjusted odds ratios and 95% confidence
intervals for presence of > 6 PVC/hr on Holter monitors across the
sMg concentration range (n = 750).
Additional file 2: Odds ratios for the fully adjusted model (Model 5)
for presence of > 6 PVC/hr on Holters are minimized using < 0.75
mmol/L sMg as the reference (n = 750).
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